Evidence map›Paper›PMID 41567527›Full record

ArticleClinical case reports2026

Burosumab in Unidentifiable Tumor-Induced Osteomalacia.

Yi Shan Der, Santosh Chaubey, Anna Mclean, Yasmin Trinh, Shelley Pember, Ashim Sinha

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yi Shan DerDepartment of Endocrinology Cairns Hospital Cairns Queensland Australia.ORCID https://orcid.org/0009-0000-5328-7082
Santosh ChaubeyDepartment of Endocrinology Cairns Hospital Cairns Queensland Australia.
Anna McleanDepartment of Endocrinology Cairns Hospital Cairns Queensland Australia.
Yasmin TrinhDepartment of Endocrinology Cairns Hospital Cairns Queensland Australia.
Shelley PemberDepartment of Pharmacy Cairns Hospital Cairns Queensland Australia.
Ashim SinhaDepartment of Endocrinology Cairns Hospital Cairns Queensland Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-induced osteomalacia (TIO) can be challenging due to underlying tumors being either unresectable or unidentifiable. Burosumab, an anti-FGF23 monoclonal antibody, has been proven to be effective in treating TIO but is currently not subsidized for this indication in Australia. Our experience suggests that burosumab should be considered a first-line treatment.

Indexed as

bone scintigraphyburosumabosteomalacia and ricketsPTH/vit D/FGF23tumor‐induced bone disease

Identifiers

PMID41567527
PMCPMC12816759

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.